HEALTHSTAT NEWS
STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
The FDA approved Takeda's Orzeyful, an orexin receptor agonist for narcolepsy type 1, marking a new class of treatments for sleep disorders. The drug demonstrated improved wakefulness and reduced symptoms compared to existing therapies in Phase 3 trials.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
- STAT+: AstraZeneca picks up FDA approval for hypertension drug
- STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
- STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more